ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1717

Progression of Radiographic Axial Damage in Patients with Psoriatic Arthritis. Relation with Clinical and Analytical Factors

Alba Quesada-Moreno1, Maria Dolores Sanchez-González2, Laura Pérez-Garrido3, Ricardo Usategui-Martín4, Guadalupe Manzano-Canabal1, Cristina Hidalgo-Calleja1, Olga Martínez-González1, Javier Del Pino-Montes1 and Carlos Alberto Montilla-Morales1, 1Rheumatology, HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA, Salamanca, Spain, 2HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA, Salamanca, Spain, 3Rheumatology, HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA, SALAMANCA, Spain, 4IBSAL, SALAMANCA, Spain

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Back pain, Biologic agents, Nonsteroidal antiinflammatory drugs (NSAIDs) and psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:   Axial involvement in psoriatic arthritis (PsA) is a controversial issue. Lack of unanimity in the definition has led to a wide range of levels of prevalence in the different series published. On the other hand, although radiographic progression in patients with spondylitis is widely known, the different radiographic characteristics of both entities advise against establishing a parallelism between the evolution of the different lesions or the clinical factors which may have an influence on them. Our objectives werw radiographic progression over four years in a group of patients with PsA and axial involvement and relate radiographic damage with clinical and analytical factors.

Methods: Prospective study with patients diagnosed with PsA according to the CASPAR criteria. Axial involvement was defined as the presence of inflammatory back pain along with sacroiliitis and/or syndesmophytes. Patients with less of five years of evolution from the onset of symptoms were included in the study. The radiographic damage was measured with the PASRI method. The difference between both measurements was four years (+ 1 month). The assessment was carried out by two observers (CM et al.). The clinical factors measured were: age, sex, peripheral involvement, smoking , use of NSAIDs (continuous vs. on-demand), biological treatment, measures of activity (BASDAI), function (BASFI) and mobility (BASMI). The following analytical variables were measured: VSG, PCR, B-CrossLaps, P1NP and HLA-B27. From a radiological perspective, the presence of a dorsal or lumbar fracture was also assessed according to the semiquantitative Gennant method.

Results: The study included 45 patients with PsA and axial involvement. The average age of patients was 53.5 years (SD: 12.9), and 31 patients were men. The kappa coefficient between both raters was 0.70. Radiographic progression was higher in men (3.13 vs. 1.14, p=0.04; in the multivariate analysis: p=0.04, OR: 0.61, 95%CI: 0.39-0.98) and in smokers (active and ex-mokers) (3.81 vs. 1.14, p=0.04; in the multivariate analysis: p=0.04, OR: 0.61, 95%CI: 0.48-0.93). Also, the presence of vertebral fracture was associated to patients with a higher radiographic progression (4.85 vs. 1.82; p=0.001; in the multivariate analysis: p=0.008, OR: 0.59, 95%CI: 0.39-0.87). No differences were found regarding the presence of peripheral manifestations (2.32 vs. 3.57, p=0.3), peripheral joints erosions (2.61 vs. 3.1, p=0.4), continuous use of NSAIDs (1.67 vs. 2.91, p=0.3), biological prescription (2.04 vs. 3.72, p=0.3) or HLA-B27 (2.00 vs. 2.79, p=0.5). A correlation was observed between radiographic progression and the initial PASRI score (p=0.001) and between progression and a lower P1NP concentration (p=0.02). Twelve patients did not show radiographic progression. These patients showed lower initial PASRI scores (5.35 vs. 12.6, p=0,001; in the multivariate analysis: p=0.03; OR: 0.73, 95%CI: 0.55-0.98) and a lower P1NP concentration (38.7 vs. 61.1; p=0.006: in the multivariate analysis: p=0.01; OR: 1.05, 95%CI: 1.008-1.096).

Conclusion: As in patients with spondylitis, male gender, smoking and the presence of initial damage were associated to a higher radiographic progression. Also, these patients were associated to a higher rate of vertebral fracture and lower levels of P1NP. Radiographic progression was not associated to inflammatory parameters, peripheral manifestations or to the treatment used. Approximately 25% of the patients did not show radiographic progression.


Disclosure: A. Quesada-Moreno, None; M. D. Sanchez-González, None; L. Pérez-Garrido, None; R. Usategui-Martín, None; G. Manzano-Canabal, None; C. Hidalgo-Calleja, None; O. Martínez-González, None; J. Del Pino-Montes, None; C. A. Montilla-Morales, None.

To cite this abstract in AMA style:

Quesada-Moreno A, Sanchez-González MD, Pérez-Garrido L, Usategui-Martín R, Manzano-Canabal G, Hidalgo-Calleja C, Martínez-González O, Del Pino-Montes J, Montilla-Morales CA. Progression of Radiographic Axial Damage in Patients with Psoriatic Arthritis. Relation with Clinical and Analytical Factors [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/progression-of-radiographic-axial-damage-in-patients-with-psoriatic-arthritis-relation-with-clinical-and-analytical-factors/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/progression-of-radiographic-axial-damage-in-patients-with-psoriatic-arthritis-relation-with-clinical-and-analytical-factors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology